Natera, INC 8-K filings

Natera Inc. announced robust second quarter 2026 financial results, showcasing significant year-over-year revenue growth, improved gross margins, and an upward revision of its full-year revenue outlook.

Natera, Inc. announced the appointment of Thomas Lynch to its Board of Directors and an amendment to a previous 8-K filing to include XBRL tagging.

Natera, Inc. announced the results of its Annual Meeting of Stockholders, including the approval of an amendment to its 2015 Equity Incentive Plan to reserve an additional 3.2 million shares.

Natera, Inc. has increased its board size to twelve members with the appointment of Dr. Thomas Lynch as an independent director.

Natera, Inc. announced the expansion of its Board of Directors to eleven members and the appointment of Eric Rubin as an independent Class I director.

Natera, Inc. announced robust financial results for Q4 and full-year 2025, driven by significant revenue growth, improved gross margins, and record test volumes.

Natera announced preliminary unaudited financial results for Q4 and full-year 2025, showing significant revenue and test volume growth driven by record Signatera expansion.

Natera, Inc. has completed the acquisition of Foresight Diagnostics, expanding its leadership in molecular residual disease detection for cancer.

Natera, Inc. reported robust third-quarter 2025 financial results, exceeding revenue expectations and raising its full-year guidance, driven by strong product growth and oncology test volumes.

Natera, a leader in cell-free DNA, announced robust second-quarter 2025 financial results, including a 32.2% revenue increase and positive cash flow, leading to an upward revision of its full-year revenue guidance.

Natera, Inc. stockholders approved an amendment to the 2015 Equity Incentive Plan, increasing shares reserved for issuance by 3.6 million, alongside the election of three Class I directors and other key proposals at its Annual Meeting on June 12, 2025.

Natera, Inc. announced a 36.5% increase in total revenues for the first quarter of 2025, reaching $501.8 million.

Natera, Inc. appoints Monica Bertagnolli to its Board of Directors, effective March 6, 2025, increasing the board size from ten to eleven members.

Natera, Inc. announces a 53% increase in Q4 revenue and a positive cash flow of $45.7 million, marking a strong finish to 2024.

Natera reports preliminary unaudited results for Q4 and full year 2024, showcasing significant revenue growth and positive cash inflows.

Natera, Inc. has amended and restated its employment agreement with Executive Chairman and Co-Founder Matthew Rabinowitz, effective November 1, 2024, outlining his compensation and severance terms.

Natera achieved record revenue growth of 63.9% and positive cash flow in Q3 2024, driven by strong product sales and increased test volumes, leading to raised full-year guidance.

Natera's second quarter results exceeded expectations with significant growth in revenue, test volume, and gross margin, leading to an increased full-year outlook.

Natera Inc. has announced its decision to redeem all of its outstanding 2.25% Convertible Senior Notes due in 2027, totaling $287.5 million.

Natera Inc. stockholders approved an amendment to the 2015 Equity Incentive Plan, increasing the share reserve by 6 million and extending the plan's term.

Natera reported a strong first quarter in 2024, achieving positive cash flow and significant revenue growth driven by increased test volumes and improved gross margins.

Natera, a cell-free DNA testing company, announced a 43.2% increase in fourth-quarter revenue and a 32% increase in full-year revenue for 2023, alongside strategic advancements and positive financial guidance for 2024.

Natera has acquired certain reproductive health assets from Invitae for an upfront payment of $10 million, with potential milestone payments of $42.5 million.